Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017
August 02 2017 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies coupled with predictive biomarkers for patient
enrichment, today announced that it will report second quarter 2017
financial results on Wednesday, August 9, 2017. Jounce
Therapeutics' management team will host a conference call and live
audio webcast to discuss these results and provide a corporate
update at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (833) 584-0037 (domestic) or (409)
350-3605 (international) and refer to conference ID 61078435. The
live webcast can be accessed under "Events & Presentations" in
the Investors and Media section of the company's website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s wesbite approximately two hours after
the call and will be available for 30 days.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in a Phase 2 trial.
For more information, please visit www.jouncetx.com.
Media Contact:
Katie Engleman
Pure Communications, Inc.
(919) 333-7722
katie@purecommunicationsinc.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024